NCT06693037View on ClinicalTrials.gov

Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy

RecruitingOBSERVATIONAL

Enrollment

2,092

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

December 31, 2031

Study Completion Date

December 31, 2031

Conditions

HER2-positive Breast Cancer

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Shu Wang

OTHER